Evidence map›Paper›PMID 38784454›Full record

ArticleRSC medicinal chemistry2024

A colorimetric assay adapted to fragment screening revealing aurones and chalcones as new arginase inhibitors.

Jason Muller, Luca Marchisio, Rym Attia, Andy Zedet, Robin Maradan, Maxence Vallet, Alison Aebischer, Dominique Harakat, François Senejoux, Christophe Ramseyer and 4 more

Abstract read
In one paragraph

Article in RSC medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jason MullerUniversité de Franche-Comté, EFS, INSERM, UMR RIGHT F-25000 Besançon France marc.pudlo@univ-fcomte.fr.ORCID https://orcid.org/0000-0003-1941-6615
Luca MarchisioUniversité de Franche-Comté, EFS, INSERM, UMR RIGHT F-25000 Besançon France marc.pudlo@univ-fcomte.fr.ORCID https://orcid.org/0009-0002-0179-2364
Rym AttiaUniversité de Franche-Comté, EFS, INSERM, UMR RIGHT F-25000 Besançon France marc.pudlo@univ-fcomte.fr.
Andy ZedetUniversité de Franche-Comté, EFS, INSERM, UMR RIGHT F-25000 Besançon France marc.pudlo@univ-fcomte.fr.
Robin MaradanUniversité de Franche-Comté, EFS, INSERM, UMR RIGHT F-25000 Besançon France marc.pudlo@univ-fcomte.fr.
Maxence ValletUniversité de Franche-Comté, EFS, INSERM, UMR RIGHT F-25000 Besançon France marc.pudlo@univ-fcomte.fr.
Alison AebischerUniversité de Franche-Comté, EFS, INSERM, UMR RIGHT F-25000 Besançon France marc.pudlo@univ-fcomte.fr.
Dominique HarakatURCATech, ICMR, CNRS UMR 7312 URCA Bât 18, BP 1039, Cedex 2 51687 Reims France.
François SenejouxUniversité de Franche-Comté, EFS, INSERM, UMR RIGHT F-25000 Besançon France marc.pudlo@univ-fcomte.fr.
Christophe RamseyerChrono-environnement UMR6249, CNRS Université de Franche-Comté F-25000 Besançon France.
Sarah FoleyChrono-environnement UMR6249, CNRS Université de Franche-Comté F-25000 Besançon France.
Bruno CardeyChrono-environnement UMR6249, CNRS Université de Franche-Comté F-25000 Besançon France.ORCID https://orcid.org/0000-0001-7420-6894
Corine GirardUniversité de Franche-Comté, EFS, INSERM, UMR RIGHT F-25000 Besançon France marc.pudlo@univ-fcomte.fr.
Marc PudloUniversité de Franche-Comté, EFS, INSERM, UMR RIGHT F-25000 Besançon France marc.pudlo@univ-fcomte.fr.ORCID https://orcid.org/0000-0002-3575-0253

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Arginase, a difficult-to-target metalloenzyme, is implicated in a wide range of diseases, including cancer, infectious, and cardiovascular diseases. Despite the medical need, existing inhibitors have limited structural diversity, consisting predominantly of amino acids and their derivatives. The search for innovative arginase inhibitors has now extended to screening approaches. Due to the small and narrow active site of arginase, screening must meet the criteria of fragment-based screening. However, the limited binding capacity of fragments requires working at high concentrations, which increases the risk of interference and false positives. In this study, we investigated three colorimetric assays and selected one based on interference for screening under these challenging conditions. The subsequent adaptation and application to the screening a library of metal chelator fragments resulted in the identification of four compounds with moderate activity. The synthesis and evaluation of a series of compounds from one of the hits led to compound 21a with an IC

Identifiers

PMID38784454
PMCPMC11110760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.